$XBI — X 투자자들은 지금 무슨 이야기를 하나

$XBIState Street SPDR S&P Biotech ETF · Asset Management · 80.8억 달러

$155.77

프리마켓+0.8%

이벤트 흐름

주요 이벤트 · 시간순

5건

2026-09-12기타악재
$XBI breaks below 50-day, technicals weaken영어 원문
Two independent technical sources flag near-term pressure; 100-day below 150-day
첫날 +0.9% · 5일 후 +0.4%
2026-07-26애널리스트호재
XBI Biotech ETF Driven by Patent Cliff, Multiple Banks Bullish on 2H26영어 원문
Morgan Stanley cites patent cliff as key driver, RBC outlines 2H26 setups, indicating dense catalysts
첫날 +0.1% · 5일 후 -2.2%

이전 이벤트 3건

2026-07-21기타악재
XBI Biotech ETF Rejected at 20-Day MA for Second Straight Session영어 원문
Multiple independent technical sources confirm XBI rejection at 20-day MA, with sector weakening since July 8, indicating fading short-term momentum.
첫날 +2.4% · 5일 후 -3.1%
2026-06-19 → 07-21M&A·자금조달악재
XBI Biotech ETF Rejected at 20D MA Two Days Running, Closes Near Lows영어 원문
Multiple independent technical analysts confirm XBI rejection at 20D MA, signaling weakening sector momentum
첫날 +3.7% · 5일 후 +8.5%
전개 과정 17회
- 2026-06-19 Multiple sources confirm multi-year high; options flow shows bullish positioning
- 2026-06-22 Multiple independent traders note XBI uptrend, citing recent M&A deals and potential targets
- 2026-06-23 Multiple independent analysts cite XBI breakout and biotech strength, extending prior M&A-active theme
- 2026-06-24 Multiple sources confirm XBI strength; valuation debate and rate expectations add new dimension
- 2026-06-25 XBI's 23.31% YTD gain nearly all landed in last two weeks of June, as big pharma races to replace ~$275B in patent expirations
- 2026-06-26 Multiple independent sources cite unusual options activity, rotation, and leadership, extending the M&A-driven trend
- 2026-06-27 Multiple sources note XBI relative strength and IONS buyout chatter, extending biotech sector momentum
- 2026-07-01 Strong H1 performance, but analysts note summer through late October is typically slow for small-cap biotechs
- 2026-07-02 Global biotech fund flows up 73% YoY; XBI nearly doubled over 13 months, while some investors trim positions
- 2026-07-04 Multiple independent traders note rotation from AI into biotech/healthcare, with XBI cited as a strong group, though some flag short-term extension.
- 2026-07-08 Multiple independent traders confirm XBI breakout, contrasting with AI sector volatility
- 2026-07-11 Multiple sources confirm XBI loses 8-10 day MAs for first time in weeks, down ~5% at peak, with rotation into mega-cap tech
- 2026-07-11 Multiple sources confirm Friday pullback but weekly breakout holds; focus on holding higher low
- 2026-07-13 Multiple independent sources confirm Friday profit-taking in pharma/biotech after a massive vertical move, with attention on 155 and 21D support.
- 2026-07-14 Multiple traders confirm XBI pullback to ~$151 and 20D MA, adding new price levels to existing pullback event
- 2026-07-16 Multiple sources confirm XBI bounced off 20-day MA; Lilly premium deal chatter acts as catalyst, extending the existing pullback-test narrative
- 2026-07-21 Multiple independent technical analysts confirm XBI rejection at 20D MA, signaling weakening sector momentum
2026-07-15애널리스트
XBI Draws Multiple Analyst Mentions Amid Momentum Dip and Catalyst Hopes영어 원문
At least three independent X users cite XBI on momentum dip, deals, and H2 catalysts
첫날 +0.5% · 5일 후 -2.6%

①

강세 vs 약세

방향별 정리 · 원문 링크

호재 요인0

아직 항목이 없어요

리스크 요인0

아직 항목이 없어요

최근 2주간 X 신뢰 작성자 의견을 AI가 묶은 주장이며, 수치는 독립 작성자 수다. 언급량은 방향을 예측하지 않는다 · 투자 권유 아님

⑩

토론

첫 댓글을 남겨 보세요

서로 존중 · 의견은 작성자 본인 책임 · 투자 권유 아님

아직 댓글이 없어요.

사실과 의견을 구분해 표시 · 모든 항목 원문 확인 가능 · 본 정보는 투자 권유를 목적으로 하지 않으며, 투자 판단과 그 결과에 대한 책임은 투자자 본인에게 있습니다.

이벤트 흐름

주요 이벤트 · 시간순

5건

2026-09-12기타악재
$XBI breaks below 50-day, technicals weaken영어 원문
Two independent technical sources flag near-term pressure; 100-day below 150-day
첫날 +0.9% · 5일 후 +0.4%
2026-07-26애널리스트호재
XBI Biotech ETF Driven by Patent Cliff, Multiple Banks Bullish on 2H26영어 원문
Morgan Stanley cites patent cliff as key driver, RBC outlines 2H26 setups, indicating dense catalysts
첫날 +0.1% · 5일 후 -2.2%
2026-07-21기타악재
XBI Biotech ETF Rejected at 20-Day MA for Second Straight Session영어 원문
Multiple independent technical sources confirm XBI rejection at 20-day MA, with sector weakening since July 8, indicating fading short-term momentum.
첫날 +2.4% · 5일 후 -3.1%
2026-06-19 → 07-21M&A·자금조달악재
XBI Biotech ETF Rejected at 20D MA Two Days Running, Closes Near Lows영어 원문
Multiple independent technical analysts confirm XBI rejection at 20D MA, signaling weakening sector momentum
첫날 +3.7% · 5일 후 +8.5%
전개 과정 17회
- 2026-06-19 Multiple sources confirm multi-year high; options flow shows bullish positioning
- 2026-06-22 Multiple independent traders note XBI uptrend, citing recent M&A deals and potential targets
- 2026-06-23 Multiple independent analysts cite XBI breakout and biotech strength, extending prior M&A-active theme
- 2026-06-24 Multiple sources confirm XBI strength; valuation debate and rate expectations add new dimension
- 2026-06-25 XBI's 23.31% YTD gain nearly all landed in last two weeks of June, as big pharma races to replace ~$275B in patent expirations
- 2026-06-26 Multiple independent sources cite unusual options activity, rotation, and leadership, extending the M&A-driven trend
- 2026-06-27 Multiple sources note XBI relative strength and IONS buyout chatter, extending biotech sector momentum
- 2026-07-01 Strong H1 performance, but analysts note summer through late October is typically slow for small-cap biotechs
- 2026-07-02 Global biotech fund flows up 73% YoY; XBI nearly doubled over 13 months, while some investors trim positions
- 2026-07-04 Multiple independent traders note rotation from AI into biotech/healthcare, with XBI cited as a strong group, though some flag short-term extension.
- 2026-07-08 Multiple independent traders confirm XBI breakout, contrasting with AI sector volatility
- 2026-07-11 Multiple sources confirm XBI loses 8-10 day MAs for first time in weeks, down ~5% at peak, with rotation into mega-cap tech
- 2026-07-11 Multiple sources confirm Friday pullback but weekly breakout holds; focus on holding higher low
- 2026-07-13 Multiple independent sources confirm Friday profit-taking in pharma/biotech after a massive vertical move, with attention on 155 and 21D support.
- 2026-07-14 Multiple traders confirm XBI pullback to ~$151 and 20D MA, adding new price levels to existing pullback event
- 2026-07-16 Multiple sources confirm XBI bounced off 20-day MA; Lilly premium deal chatter acts as catalyst, extending the existing pullback-test narrative
- 2026-07-21 Multiple independent technical analysts confirm XBI rejection at 20D MA, signaling weakening sector momentum
2026-07-15애널리스트
XBI Draws Multiple Analyst Mentions Amid Momentum Dip and Catalyst Hopes영어 원문
At least three independent X users cite XBI on momentum dip, deals, and H2 catalysts
첫날 +0.5% · 5일 후 -2.6%

$XBI (State Street SPDR S&P Biotech ETF) — X 투자자 토론

$XBI 종목을 가장 많이 언급한 신뢰 작성자

$XBI 종목이 등장한 최근 헤드라인

$XBI (State Street SPDR S&P Biotech ETF) — X 투자자 토론

$XBI 종목을 가장 많이 언급한 신뢰 작성자

$XBI 종목이 등장한 최근 헤드라인

이벤트 흐름

$XBI breaks below 50-day, technicals weaken영어 원문

XBI Biotech ETF Driven by Patent Cliff, Multiple Banks Bullish on 2H26영어 원문

XBI Biotech ETF Rejected at 20-Day MA for Second Straight Session영어 원문

XBI Biotech ETF Rejected at 20D MA Two Days Running, Closes Near Lows영어 원문

XBI Draws Multiple Analyst Mentions Amid Momentum Dip and Catalyst Hopes영어 원문

강세 vs 약세

토론

이벤트 흐름

$XBI breaks below 50-day, technicals weaken영어 원문

XBI Biotech ETF Driven by Patent Cliff, Multiple Banks Bullish on 2H26영어 원문

XBI Biotech ETF Rejected at 20-Day MA for Second Straight Session영어 원문

XBI Biotech ETF Rejected at 20D MA Two Days Running, Closes Near Lows영어 원문

XBI Draws Multiple Analyst Mentions Amid Momentum Dip and Catalyst Hopes영어 원문